Endocrinology

Semaglutide shows promise in reducing heart failure events in patients with HFpEF

Semaglutide significantly reduces the risk of heart failure events, including worsening heart failure, in patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF), though its effect on cardiovascular death alone was not significant, according to a study. A post-hoc analysis pooled data from 4 randomized trials—SELECT, FLOW,...